Caribou Biosciences, Inc. Share Price
CRBUCaribou Biosciences, Inc. Stock Performance
Open $1.81 | Prev. Close $1.76 | Circuit Range N/A |
Day Range $1.75 - $1.81 | Year Range $1.23 - $3.54 | Volume 80,835 |
Average Traded $1.77 |
Caribou Biosciences, Inc. Share Price Chart
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Caribou Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Jun-26 | $1.81 | $1.75 | +0.00% |
30-Jun-26 | $1.81 | $1.75 | -0.57% |
29-Jun-26 | $1.69 | $1.76 | +5.39% |
26-Jun-26 | $1.57 | $1.67 | +7.05% |
25-Jun-26 | $1.68 | $1.56 | -5.74% |
24-Jun-26 | $1.67 | $1.66 | -0.60% |
23-Jun-26 | $1.64 | $1.67 | +1.52% |